AD

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

Logo Benzinga
Benzinga
By Vandana Singh

Cassava Sciences Inc SAVA shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam.

AD
AD

Among the latest concerns highlighted in the NYT article include a report that on March 30, the scientific journal PLoS One retracted five papers authored by Dr. H.Y. Wang, a Cassava (SAVA) adviser.

The decision followed a five-month investigation into serious concerns about the integrity and reliability of the results, The Times reported citing a spokesman for the journal.

In December, in response to the allegations, The Journal of Neuroscience published expressions of concern regarding two brain studies authored by the company's chief collaborator, Hoau-Yan Wang.

One was co-written by Lindsay H. Burns, the chief scientist at Cassava. The journal editors also noted errors in the images accompanying the latter study.

Meanwhile, Dr. Roger Nicoll, a neuroscientist at the University of California, San Francisco, raised concerns that taxpayers' money was being used for the company's studies. The National Institutes of Health (NIH) has provided Cassava with more than $20 million for its research.

Continue read on benzinga.com

AD
Logo InvestorPlace
Cassava Sciences (NASDAQ: SAVA ) stock is tumbling 16% in morning trading in the wake of an article on the company by The New York Times. Reporter Apoorva...

Logo The New York Times
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals. A small biotech company that...

Logo InvestorPlace
Cassava Sciences ( SAVA ) is risky but worthwhile after clarity emerges following scandal. The biotech company is well-funded and has blockbuster potential...

Logo Nasdaq
Its been a miserable week for investors in clinical-stage biotechnology company Cassava Sciences ( SAVA ). The stock tumbled over 20% following a fireside...

Logo Benzinga
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Logo Nasdaq
Betting on turnarounds in companies that others are too scared to touch can be a successful strategy for some investors. That's because the market often...

Logo Benzinga
Treatment with Bryostatin shown to increase blood vessel health, a key factor for prevention and disease reversal National Institutes of Health...

Logo InvestorPlace
Cassava Sciences (NASDAQ: SAVA ) stock is falling on Tuesday as investors react to a recent fireside chat from CEO Remi Barbier. Source: Postmodern Studio /...

Logo CNN
Markets23 Mar
(CNN)Having high cholesterol and blood sugar in your 30s may raise your risk for Alzheimer's disease decades later in life, according to a new study....

Logo Benzinga
[TODAY IS YOUR LUCKY DAY] Get 50% OFF and get 2 bear market beating options trade straight to your inbox and SMS every month! Click Here Now to Get Started!...

Logo Benzinga
NEW YORK, March 29, 2024 /PRNewswire/ --Synaptogenix, Inc.SNPX (Synaptogenix or the Company), an emerging biopharmaceutical company developing regenerative...

Logo EIN Presswire
WRFs grant will enable University of Washington professor to address protein tangles believed to contribute to destruction of brain neurons WRFs generous...

Logo Nasdaq
MarketsBy Reuters 1 Apr
By Jake Spring April 1 (Reuters) - The U.N. climate science panel publishes its final report in the current assessment cycle on Monday, and this time will...

Logo Benzinga
Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK, April 12,...

Logo The New York Times
A late-stage trial was halted after strong early results, according to the company, but outside scientists have not yet seen the data. An experimental drug...

Logo CNN
CNN — An Australian TV host is due to face trial in China Thursday for allegedly sharing state secrets in an opaque case that analysts worry may be...

Logo Benzinga
MENLO PARK, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- CohBar, Inc. CWBR, a clinical stage biotechnology company leveraging the power of the mitochondria and...

Logo EIN Presswire
PRODEO is looking for promising companies in the field of brain health. The US brain health market is the largest in the world and incredibly dynamic....

Logo Benzinga
Capricor Therapeutics Inc CAPR announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for...

Logo CNBC
Key Points Top FDA official Dr. Peter Marks told the drug regulator's advisory committee that a decision needs to be made on updating Covid vaccines to...